Last reviewed · How we verify
ONO-7018
At a glance
| Generic name | ONO-7018 |
|---|---|
| Sponsor | Ono Pharmaceutical Co. Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL (PHASE1)
- A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONO-7018 CI brief — competitive landscape report
- ONO-7018 updates RSS · CI watch RSS
- Ono Pharmaceutical Co. Ltd portfolio CI